Skip to main content

Table 1 Characteristics of documented male patients with advanced prostate cancer (total number = 1273)

From: A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients

Demographic data: mean (minimum, maximum)

Age (years)

75 (50, 97)

Weight (kg)

81 (45, 160)

Height (cm)

175 (157, 198)

Diagnosis/findings: mean

Time since first diagnosis (months)

33

Biopsy: Number of cores

8.2

ā€ƒā€ƒā€ƒNumber of positive cores

4.5

cT1-2, %

44

cT3-4, %

32

M+, %

20

Gleason grade (1-5)

3.4

Gleason sum (2-10)

6.8

Therapy with GnRH analogues: number of patients (%)

First-time treatment

610 (48)

Pre-treatment*

652 (51)

ā€ƒā€ƒā€ƒ3 monthly leuprolide acetate

210 (32.2)

ā€ƒā€ƒā€ƒLeuprolide acetate, Takeda Pharmaceutical

168 (25.8)

ā€ƒā€ƒā€ƒGoserelin acetate, AstraZenca

107 (16.4)

ā€ƒā€ƒā€ƒBuserelin acetate, Sanofi-Aventis

97 (14.9)

ā€ƒā€ƒā€ƒ1 monthly leuprolide acetate

27 (4.1)

ā€ƒā€ƒā€ƒLeuprorelin acetate, Takeda Pharmaceutical

21 (3.2)

ā€ƒā€ƒā€ƒOther drugs

22 (3.4)

ā€ƒā€ƒā€ƒMissing data

15 (2.3)

  1. *Percentage refers to patients with change of therapy (n = 652). Total n = 667 includes multiple namings: single n = 637; 2-fold: n = 15